Open AccessAdherence to self-administered biologic disease-modifying antirheumatic drugs across health-system specialty pharmacies
Author(s) -
Autumn Zuckerman,
Josh DeClercq,
Leena Choi,
Nicole Cowgill,
Kate McCarthy,
Brian Lounsbery,
Rushabh Shah,
Amanuel Kehasse,
Karen C. Thomas,
Louis Sokos,
Martha Stutsky,
Jennifer L. Young,
Jennifer Carter,
Monika Lach,
Kelly Wise,
Toby Thomas,
Melissa Ortega,
Jin-Kyu Lee,
Kate Marie Lewis,
Jillian Dura,
Nicholas P Gazda,
Lana Gerzenshtein,
Scott Canfield
Publication year - 2021
Publication title -
american journal of health-system pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.487
H-Index - 96
eISSN - 1535-2900
pISSN - 1079-2082
DOI - 10.1093/ajhp/zxab342
Subject(s) - medicine , interquartile range , pharmacy , medical prescription , cohort , antirheumatic drugs , specialty , rheumatoid arthritis , retrospective cohort study , disease , emergency medicine , antirheumatic agents , family medicine , pharmacology
Adherence to self-administered biologic disease-modifying antirheumatic drugs (bDMARDs) is necessary for therapeutic benefit. Health-system specialty pharmacies (HSSPs) have reported high adherence rates across several disease states; however, adherence outcomes in rheumatoid arthritis (RA) populations have not yet been established.